SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

MediWound Reports Third Quarter 2026 Financial Results and Provides Corporate Update

EscharEx® Phase III VALUE Trial Advancing; Interim Assessment and Enrollment Completion Expected by

MDWD

Related stories